Skip to main content
Clinical Trials/NCT06865560
NCT06865560CompletedNot Applicable

Emotional Awareness and Expression Therapy for Chronic Pain and Opioid Use Disorder - A Pilot Study

University of Michigan1 site in 1 country11 target enrollmentStarted: June 3, 2025Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
11
Locations
1
Primary Endpoint
Mean scores on the Treatment Acceptability and Adherence Scale (TAAS) at the post intervention timepoint.

Study Overview

Brief Summary

The study is intended to test whether a group-based Zoom behavioral treatment can help adults with chronic pain and opioid use disorder (OUD) learn effective strategies for reducing pain, disability and other problems that can come with these conditions (such as depression, anxiety, and difficulty managing emotions).

Detailed Description

Emotional Awareness and Expression Therapy (EAET) is a behavioral therapy that focuses on reducing chronic pain by helping people work on the effects of stress, trauma, and emotions that they have experienced in their lives. It is delivered in group sessions of 5-7 individuals by trained therapists who treat emotions or problems in relationships to reduce chronic pain. Pain decreases through increased recognition and expression of emotions, and learning to feel safe in the presence of emotions.

The primary aim of the study is to demonstrate the feasibility, acceptability, and preliminary efficacy of the proposed EAET intervention in adults with chronic pain and opioid use disorder.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Be able to read, write and speak English
  • •Have Internet access and audio-visual conferencing capability (e.g., Zoom meetings by phone or computer) in the home
  • •Widespread pain and has opioid use disorder (OUD)

Exclusion Criteria

  • •Diagnosis of autoimmune disease, spinal cord injury, cancer.
  • •Currently receiving cognitive-behavioral therapy, EAET, or other psychological therapies for pain
  • •Open litigation regarding chronic pain in the past 1 year, as assessed in preliminary study screening.
  • •Inability to provide informed consent and complete study procedures (e.g., indications of suspected major cognitive impairment via observations of study staff during consenting) that would preclude comprehension or participation in study protocols.
  • •Pregnant or breastfeeding
  • •Any other diseases or conditions that would make a patient unsuitable for study participation as determined by the site principal investigators.

Arms & Interventions

Emotional Awareness and Expression Therapy (EAET)

Experimental

Adults with chronic pain and mild to moderate opioid use disorder (OUD).

Intervention: Emotional Awareness and Expression Therapy (EAET) (Behavioral)

Outcomes

Primary Outcomes

Mean scores on the Treatment Acceptability and Adherence Scale (TAAS) at the post intervention timepoint.

Time Frame: Approximately day 70

The TAAS is a validated instrument for behavioral interventions. Although no validated cutoff scores exist for this measure, prior research has used an informal cutoff score at the midpoint of the total score (i.e., 35 out of a possible 70) as a measure of moderate acceptability. If the EAET intervention is ineffective, low acceptability may be an explanatory factor. - scores above the midpoint - 35 out of 70 - will denote moderate acceptability of the intervention

Feasibility: Session attendance

Time Frame: Approximately day 70

Feasibility: Combined completion of in-session and between-session practices

Time Frame: Approximately day 70

Secondary Outcomes

  • Change in Brief Pain Inventory (BPI) pain intensity(Day 1 and up to day 160)
  • Change in Pain-related OUD Exacerbation Scale (PrOUD-ES)(Day 1 and up to day 160)
  • Change in Opioid Craving Visual Analog Scale (OC-VAS)(Day 1 and up to day 160)
  • Change in Current Opioid Misuse Measure-Brief (COMM-9)(Day 1 and up to day 160)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

John Sturgeon

Clinical Assistant Professor of Anesthesiology

University of Michigan

Study Sites (1)

Loading locations...

Similar Trials

Emotional Awareness and Expression Therapy... | Clinical Trial